Aziz Nazha, MD, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Aziz Nazha, MD
Advertisement
Articles by Aziz Nazha, MD
Advertisement
Latest Updated Articles
Dr. Nazha on a Mutational Model to Predict Response to Hypomethylating Agents in MDSPublished: September 18th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
